Table 26 Immunomodulatory therapies used among those who used antibiotic therapy
From: Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy
|  | Total (n = 13,932) | No. (%) | With antibiotics n = 12,238 (%) | Without antibiotics n = 1498 (%) | p value |
|---|---|---|---|---|---|
Use of lopinavir/ritonavir | 13,719 | 8414 (61.3) | 7590 (62.1) | 824 (55.0) | < 0.001 |
Use of hydroxychloroquine | 13,727 | 11,727 (85.4) | 10,677 (87.3) | 1050 (70.1) | < 0.001 |
Use of beta-Interferon | 13,662 | 1585 (11.6) | 1488 (12.2) | 97 (6.5) | < 0.001 |
Use of tocilizumab | 13,703 | 1145 (8.4) | 1106 (9.1) | 39 (2.6) | < 0.001 |
Use of anakinra | 13,604 | 76 (0.6) | 76 (0.6) | 0 (0) | < 0.001 |
Use of systemic corticosteroids | 13,689 | 4738 (34.6) | 4500 (36.9) | 238 (16.0) | < 0.001 |
Use of immunoglobulin | 13,483 | 62 (0.5) | 60 (0.5) | 2 (0.1) | 0.06 |